Alliance for Pandemic Preparedness

June 1, 2020

Efficacy and Safety of Interferon Beta-1a in Treatment of Severe COVID-19 A Randomized Clinical Trial

Category:

Topic:

  • [pre-print, not peer reviewed] Davoudi-Monfared et al. report the results of a randomized trial evaluating the efficacy and safety of interferon β-1a (IFN) in patients with severe COVID-19, which showed no significant difference of time to clinical response between the IFN and the control groups (9.7 ± 5.8 vs. 8.3 ± 4.9 days). The IFN group had a higher discharge rate on day 14 and lower 28-day mortality (66.7% vs. 43.6% and 19.0% vs. 38.5%, respectively). 

Davoudi-Monfared et al. (May 30, 2020). Efficacy and Safety of Interferon Beta-1a in Treatment of Severe COVID-19 A Randomized Clinical Trial. Pre-print downloaded June 1 from https://doi.org/10.1101/2020.05.28.20116467